Redwood City, CA, United States of America

Thorsten A Kirschberg

This inventor holds 44 USPTO granted patents and 20 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Antiviral Compounds. Top assignees: Gilead Sciences, Inc., Gilead Pharmasset LLC, Terns Pharmaceuticals, Inc.. Active years: 2008-2026.

USPTO Granted Patents = 44 (Patent Applications = 20)

% Patents Active = 79.5

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 19)

Average Co-Inventor Count = 9.3

ph-index = 16

Forward Citations = 698(Granted Patents)

Location History:

Belmont, CA (US) (2008 - 2012)
Foster City, CA (US) (2012)
Redwood City, CA (US) (2013 - 2018)
San Carlos, CA (US) (2018 - 2024)

Company Filing History:

28 out of 946

Gilead Sciences, Inc.

patents

4 out of 81

Gilead Pharmasset LLC

patents

4 out of 13

Terns Pharmaceuticals, Inc.

Korea Research Institute of Chemical Technology

patents

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

Antiviral Compounds

GLP-1R Agonists

Thyroid Hormone Receptor

Tyrosine Kinase Inhibitors

Pyrrolizine Compounds

Phosphonate Analogues

Crystalline Forms

Cancer Treatment

COT Modulators

HIV Inhibitors

Benzoimidazoles

Anti-inflammatory Compounds

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12617783 - Heterocyclic GLP-1R agonists (2026-05-05),

2. 12528791 - Thyroid hormone receptor beta agonist compounds (2026-01-20),

3. 12454524 - (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias (2025-10-28),

4. 12398127 - Thyroid hormone receptor beta agonist compounds (2025-08-26),

5. 12240835 - Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity (2025-03-04),

6. 12215113 - Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide] (2025-02-04),

7. 12161625 - Substituted pyrrolizine compounds and uses thereof (2024-12-10),

8. 11945785 - Pyrazine compounds as inhibitors of FLT3 (2024-04-02),

9. 11905299 - Cot modulators and methods of use thereof (2024-02-20),

10. 11203587 - Thyroid hormone receptor beta agonist compounds (2021-12-21),

11. 11066414 - Cot modulators and methods of use thereof (2021-07-20),

12. 10919911 - Tricyclic ASK1 inhibitors (2021-02-16),

13. 10889571 - Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias (2021-01-12),

14. 10874640 - Substituted pyrrolizine compounds and uses thereof (2020-12-29),

15. 10800767 - Thyroid hormone receptor beta agonist compounds (2020-10-13),

Title: The Innovative Journey of Thorsten A Kirschberg

Introduction: Thorsten A Kirschberg is a renowned inventor based in Redwood City, CA (US) known for his groundbreaking contributions to various fields.

Latest Patents: Thorsten A Kirschberg holds several patents in the areas of technology, healthcare, and sustainability, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, Thorsten A Kirschberg has worked with leading companies to develop cutting-edge solutions that have revolutionized industries.

Collaborations: Throughout his career, Thorsten A Kirschberg has collaborated with top researchers, engineers, and scientists to bring his innovative ideas to life, resulting in impactful inventions.

Conclusion: Thorsten A Kirschberg's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.